Updates are available Correction dated 2024-12-30
Click to view Correction: https://doi.org/10.1007/s00262-024-03873-5
-
Authors
De Jaeghere, Emiel A.
Tuyaerts, Sandra
Van Nuffel, An M. T.
Belmans, Ann
Bogaerts, Kris
Baiden-Amissah, Regina
Lippens, Lien
Vuylsteke, Peter
Henry, Stéphanie
Trinh, Xuan Bich
van Dam, Peter A.
Aspeslagh, Sandrine
De Caluwé, Alex
Naert, Eline
Lambrechts, Diether
Hendrix, An
De Wever, Olivier
Van de Vijver, Koen K.
Amant, Frédéric
Vandecasteele, Katrien
Denys, Hannelore G.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03192059 at ClinicalTrials.govDocuments that mention this clinical trial
2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial
https://doi.org/10.1136/ijgc-2022-esgo.401
Role of stereotactic body radiotherapy in gynecologic radiation oncology
https://doi.org/10.1136/ijgc-2021-002466
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
https://doi.org/10.1007/s00262-022-03253-x
Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin
https://doi.org/10.1136/ijgc-2020-001227
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (1195919N, T002218N)
Kom op tegen Kanker (ZKD5584)
ERA-NET-Transcan-2 (G0H7516N)
Nationale Loterij (SW/OPS/SUB 11719-0001)
- License Information
-
More Information
Article History
Received: 30 March 2022
Accepted: 4 July 2022
First Online: 12 August 2022
Change Date: 1 September 2022
Change Type: Update
Change Details: There was an unusual spacing in Table 1 and it has been corrected.
Change Date: 30 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00262-024-03873-5
Declarations
:
: EAD: travel and accommodation expenses (institutional, not personal) from AstraZeneca, GSK, Pfizer, and PharmaMar. AMTV: became an employee for GSK during the publication development. PV: consulting or advisory role (personal) from Eli Lily and Company, MSD, Mundipharma, Novartis, Pfizer, and Roche; research funding from Tesaro. SH: consulting or advisory role (personal) from AstraZeneca, BMSi, Gilead Sciences, Merck, MSD Oncology, Novartis, and Sanofi. SA: consulting or advisory role (institutional, not personal) for MSD, Sanofi, Roche, BMS, and Pfizer; research funding (institutional, not personal) from Sanofi. AD: research funding (institutional, not personal) from AstraZeneca. EN: travel and accommodation expenses (institutional, not personal) from AstraZeneca, Novartis, Pfizer, PharmaMar, Roche, and Teva. DL: consulting or advisory role (institutional, not personal) for AstraZeneca, Biocartis, BMS, Boehringer Ingelheim, Eli Lilly and Company, Hedera Dx, Montis Biosciences, MSD; consulting or advisory role (personal) for AstraZeneca, Biocartis, Montis Biosciences, and MSD. FA: consulting or advisory role (institutional, not personal) for MiMark. KV: travel and accommodation expenses (institutional, not personal) from PharmaMar. HGD: travel and accommodation expenses (institutional, not personal) from Amgen, AstraZeneca, Eli Lily and Company, GSK, MSD, Novartis, Pfizer, PharmaMar, Roche, Tesaro, and Teva; research funding (institutional, not personal) from Roche. ST, AB, KB, RB, LL, XBT, PAV, AH, OD, and KKV: declare no competing interests.
: The study protocol and amendments were approved by the independent ethics committee or review board at each participating institution (Ghent University Hospital ethics committee, identifier EC/2017/0304); all patients provided written informed consent. The study was conducted in compliance with local and national regulations and in accordance with the Declaration of Helsinki and the International Council for Harmonization Guidelines for Good Clinical Practice. The findings have been reported according to the (applicable parts of) Consolidated Standards of Reporting Trials guidelines.
: Not applicable.
